CytomX Therapeutics
CTMX
122 hedge funds and large institutions have $614M invested in CytomX Therapeutics in 2025 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 20 closing their positions.
1,607% more call options, than puts
Call options by funds: $6.14M | Put options by funds: $360K
95% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 20
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
40% more capital invested
Capital invested by funds: $438M → $614M (+$176M)
18% more funds holding
Funds holding: 103 → 122 (+19)
1.71% more ownership
Funds ownership: 83.33% → 85.05% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.3M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$20.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.1M |
| 4 |
EP
Eversept Partners
New York
|
+$9.52M |
| 5 |
Financial Engines Advisors
Santa Clara,
California
|
+$9.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$35.3M |
| 2 |
O
OrbiMed
New York
|
-$18.8M |
| 3 |
RI
RTW Investments
New York
|
-$11M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$8.49M |
| 5 |
Renaissance Technologies
New York
|
-$8.12M |
CTMX Hedge Fund Activity: Q4 2025 in Review
122 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2025, worth a combined $614M — up 40% from $438M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CTMX positions and 20 closed out — a net gain of 19 holders — while 39 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $35.3M. The largest seller was Tang Capital Management, exiting entirely with an estimated $35.3M sold.
- 122 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2025, up from 103 in Q3 2025.
- Funds reported $614M of CytomX Therapeutics stock for Q4 2025, up 40% quarter-over-quarter.
- 39 funds opened new CytomX Therapeutics positions in Q4 2025 and 20 closed out, a net change of +19 holders.
- The largest CytomX Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $35.3M added.
- The largest CytomX Therapeutics seller in Q4 2025 was Tang Capital Management, an estimated $35.3M sold.
Based on aggregated 13F filings for Q4 2025.